GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharnext SA (XPAR:ALPHA) » Definitions » Deferred Policy Acquisition Costs

Pharnext (XPAR:ALPHA) Deferred Policy Acquisition Costs


View and export this data going back to 2016. Start your Free Trial

What is Pharnext Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Pharnext (XPAR:ALPHA) Business Description

Industry
Traded in Other Exchanges
Address
11-13 Rue Rene Jacques, Issy-Les-Moulineaux, FRA, 92130
Pharnext SA is a biopharmaceutical company developing treatments targeting neurodegenerative diseases. The company also develop a Pleotherapy technology platform. Its product in the pipeline includes SYNGILITY; PXT3003 and PXT864. The company's only segment being research and development on new pharmaceutical therapies based on Pleotherapy.